Biotech News
Related news
PepGen
Oligonucleotide Delivery Company PepGen develops Enhanced Delivery Oligonucleotides intended to transport therapeutic oligonucleotides into skeletal muscle. PGN-EDODM1 PGN-EDODM1 is designed to correct RNA splicing in myotonic dystrophy type 1 by releasing pathogenic RNA and restoring downstream protein expression. FREEDOM2 The FREEDOM2...
Recent company news
PEPGPepGen2026-11-12 03:22 EST
PepGen Announces Pricing of $125 Million Public Offering
PEPGPepGen2026-11-10 21:23 EST
PepGen Announces Proposed $125.0 Million Public Offering of Common Stock
PEPGPepGen2026-11-10 12:05 EST
PepGen Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
PEPGPepGen2026-11-10 12:01 EST
PepGen Announces Positive Phase 2 FREEDOM2-DM1 10 mg/kg Results Demonstrating Highest Reported Splicing Correction and Improvements Across Multiple Functional Measures
PEPGPepGen2026-08-06 11:32 EST
PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Stock data
- Close
- 3.93 USD
- Market cap
- 100.3M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States
